Drugmakers — major beneficiaries of NIH-backed university research — have been largely silence on the Trump administration's cuts to agency research payments.
The company projects portfolio receipts for 2025 to range between $2.9 billion and $3.05 billion, representing 4-9% growth. Guidance incorporates scenarios for key products like Vertex's new triple ...
For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...
Vertex reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Trikafta/Kaftrio ...
Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex ...
Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares.
Vertex reported solid fourth-quarter numbers throughout its business. While the company's earnings per share came in slightly ...
Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net cash provided by operating activities of $743 million in ...
Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...
Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...
RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $407 from $402 and keeps a Sector Perform rating on the shares.
Vertex Pharmaceuticals Inc. will soon lose a member of its leadership team that helped the company achieve major revenue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results